 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8990919293949596979899100101» |
- ||||| Avastin (bevacizumab) / Roche
New P2 trial, Metastases: BOOSTER: Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (clinicaltrials.gov) - Nov 19, 2013
P2, N=160, Recruiting, Sponsor: Japan Breast Cancer Research Group
- |||| Kisqali (ribociclib) / Novartis
Enrollment open: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) (clinicaltrials.gov) - Nov 19, 2013
P2, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting
- | letrozole / Generic mfg., everolimus / Generic mfg.
Biomarker, New P2 trial, IO biomarker, Metastases: A pilot, phase II, unblinded, single-arm study to evaluate how biomarkers of hormonal resistance work against treatment with everolimus plus letrozol in first line treatment of postmenopausal women with hormone positive metastatic or locallyadvanced breast cancer Estudio piloto de fase II, no enmascarado y con un solo brazo de tratamiento para evaluar como actuan los biomarcadores de resistencia hormonal frente al tratamiento con everolimus y letrozol en primera l (EUDRACT) - Nov 11, 2013
P2, N=53, Ongoing, Sponsor: Novartis Farmac
- letrozole / Generic mfg.
Enrollment change: Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Nov 3, 2013
P=N/A, N=420, Recruiting, Sponsor: Heilongjiang University of Chinese Medicine
Not yet recruiting --> Recruiting N=160 --> 420
- ||| Ibrance (palbociclib) / Pfizer
Enrollment closed, Combination therapy, Metastases: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Oct 31, 2013
P1/2, N=58, Active, not recruiting, Sponsor: Pfizer
N=160 --> 420 Recruiting --> Active, not recruiting
- ||||| Herceptin (trastuzumab) / Roche
New P2 trial: PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (clinicaltrials.gov) - Oct 29, 2013
P2, N=150, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
- tamoxifen / Generic mfg.
Enrollment closed: LOGRIBMET: Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer (clinicaltrials.gov) - Oct 27, 2013
P=N/A, N=115, Active, not recruiting, Sponsor: University of Michigan Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Herceptin (trastuzumab) / Roche
Enrollment open: PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (clinicaltrials.gov) - Oct 24, 2013
P2, N=150, Recruiting, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- letrozole / Generic mfg.
Enrollment change, Surgery: Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Oct 14, 2013
P=N/A, N=200, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Not yet recruiting --> Recruiting N=125 --> 200
- metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Oct 7, 2013
P2, N=64, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=125 --> 200 Not yet recruiting --> Recruiting
- |||||||||| Kisqali (ribociclib) / Novartis
New P3 trial: MONALEESA-2: Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - Oct 6, 2013
P3, N=500, Recruiting, Sponsor: Novartis Pharmaceuticals
- | letrozole / Generic mfg.
New P4 trial: The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization. (clinicaltrials.gov) - Sep 5, 2013
P4, N=100, Not yet recruiting, Sponsor: P?nar
- ||| letrozole / Generic mfg., dasatinib / Generic mfg.
Enrollment closed, Metastases: Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic (clinicaltrials.gov) - Sep 2, 2013
P2, N=120, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Enrollment closed, Combination therapy, Metastases: Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Aug 22, 2013
P4, N=73, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Cetrotide (cetrorelix) / EMD Serono
New P4 trial: Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders (clinicaltrials.gov) - Aug 18, 2013
P4, N=500, Not yet recruiting, Sponsor: Huang Rui
- ||||| Piqray (alpelisib) / Novartis, buparlisib (AN2025) / Novartis, Adlai Nortye
New P2 trial: Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women (clinicaltrials.gov) - Aug 13, 2013
P2, N=360, Recruiting, Sponsor: Novartis Pharmaceuticals
- goserelin acetate / Generic mfg., letrozole / Generic mfg., anastrozole / Generic mfg.
Trial termination: Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov) - Aug 8, 2013
P2, N=8, Terminated, Sponsor: Washington University School of Medicine
Recruiting --> Active, not recruiting Suspended --> Terminated; Due to funding source and lack of accrual
- goserelin acetate / Generic mfg., letrozole / Generic mfg., anastrozole / Generic mfg.
Enrollment change: Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer (clinicaltrials.gov) - Aug 8, 2013
P2, N=8, Terminated, Sponsor: Washington University School of Medicine
Suspended --> Terminated; Due to funding source and lack of accrual N=175 --> 8
- | letrozole / Generic mfg.
Trial completion, Surgery: Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery (clinicaltrials.gov) - Aug 7, 2013
P3, N=756, Completed, Sponsor: Imperial Cancer Clinical Research Unit
N=175 --> 8 Recruiting --> Completed
- ||||| Kisqali (ribociclib) / Novartis
New P2 trial: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) (clinicaltrials.gov) - Aug 6, 2013
P2, N=120, Recruiting, Sponsor: Novartis Pharmaceuticals
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy (clinicaltrials.gov) - Aug 5, 2013
P=N/A, N=8, Completed, Sponsor: University of Washington
Recruiting --> Completed N=20 --> 8
- Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy (clinicaltrials.gov) - Aug 5, 2013
P=N/A, N=8, Completed, Sponsor: University of Washington
N=20 --> 8 Active, not recruiting --> Completed
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Enrollment closed: Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole (clinicaltrials.gov) - Aug 1, 2013
P=N/A, N=40, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Farydak (panobinostat) / Secura Bio
Trial suspension, Metastases: Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Jul 25, 2013
P1/2, N=48, Suspended, Sponsor: North Central Cancer Treatment Group
Recruiting --> Active, not recruiting Recruiting --> Suspended
- | letrozole / Generic mfg.
Biomarker, New P4 trial, Adverse events: Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) (clinicaltrials.gov) - Jul 23, 2013
P4, N=3545, Active, not recruiting, Sponsor: Institut fuer Frauengesundheit
- letrozole / Generic mfg.
Biomarker, Enrollment closed, Adverse events: Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace) (clinicaltrials.gov) - Jul 23, 2013
P4, N=3545, Active, not recruiting, Sponsor: Institut fuer Frauengesundheit
Recruiting --> Suspended Not yet recruiting --> Active, not recruiting
- RG4733 / Roche
Trial termination: RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer (clinicaltrials.gov) - Jun 30, 2013
P1, N=28, Terminated, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Terminated
- letrozole / Generic mfg.
Enrollment open: T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin (clinicaltrials.gov) - Jun 25, 2013
P1/2, N=60, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Terminated Not yet recruiting --> Recruiting
- ||| Enrollment closed: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy (clinicaltrials.gov) - Jun 12, 2013
P2, N=300, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Trial initiation date: T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin (clinicaltrials.gov) - Jun 11, 2013
P1/2, N=60, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting Initiation date: Dec 2012 --> Jun 2013
- ||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
New P1/2 trial, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Jun 5, 2013
P1/2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Piqray (alpelisib) / Novartis
New P1 trial, Metastases: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 4, 2013
P1, N=56, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- ||| Piqray (alpelisib) / Novartis
Enrollment open, Metastases: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Jun 2, 2013
P1, N=56, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Initiation date: Dec 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- tamoxifen / Generic mfg.
Trial completion: OXYTAM: Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not (clinicaltrials.gov) - Jun 2, 2013
P4, N=29, Completed, Sponsor: Institut Claudius Regaud
Not yet recruiting --> Recruiting Recruiting --> Completed
- letrozole / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Metastases: Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer (clinicaltrials.gov) - May 22, 2013
P1/2, N=55, Active, not recruiting, Sponsor: University of Medicine and Dentistry New Jersey
Recruiting --> Completed Recruiting --> Active, not recruiting
- linsitinib (ASP7487) / Sling Therap
Enrollment change, Combination therapy, Metastases: Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer (clinicaltrials.gov) - May 21, 2013
P2, N=0, Withdrawn, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting N=178 --> 0
- zoledronic acid / Generic mfg.
Enrollment closed: Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms (clinicaltrials.gov) - May 14, 2013
P2, N=55, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=178 --> 0 Recruiting --> Active, not recruiting
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion: PPCOSII: Pregnancy in Polycystic Ovary Syndrome II (clinicaltrials.gov) - May 9, 2013
P3, N=750, Completed, Sponsor: Yale University
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- vatalanib (PTK787) / Novartis, Bayer
Trial termination, Metastases: PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - May 5, 2013
P2, N=4, Terminated, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Completed --> Terminated; unacceptable toxicity
- vatalanib (PTK787) / Novartis, Bayer
Enrollment change, Metastases: PTK and Letrozole in Post-menopausal Women With Advanced Breast Cancer (clinicaltrials.gov) - May 5, 2013
P2, N=4, Terminated, Sponsor: Washington University School of Medicine
Completed --> Terminated; unacceptable toxicity N=32 --> 4
- sorafenib / Generic mfg.
Enrollment change, Combination therapy, Metastases: A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer (EUDRACT) - Apr 19, 2013
P2, N=220, Ongoing, Sponsor: FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI`FONDAZIONE MICHELANGELO
N=32 --> 4 N=80 --> 220
- letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment change: Phase II study of the combination of RAD001 and Letrozole in patients with recurrent endometrial cancer (EUDRACT) - Apr 19, 2013
P2, N=78, Terminated, Sponsor: Oncology Institute of Southern Switzerland
N=80 --> 220 N=30 --> 78
- | dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment open, Combination therapy, Metastases: Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer (clinicaltrials.gov) - Apr 18, 2013
P1/2, N=36, Recruiting, Sponsor: Georgetown University
N=30 --> 78 Active, not recruiting --> Recruiting
- ||| voxtalisib (SAR245409) / Sanofi, pilaralisib (SAR245408) / Sanofi
Enrollment change, Combination therapy: Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer (clinicaltrials.gov) - Apr 8, 2013
P1/2, N=72, Completed, Sponsor: Sanofi
Active, not recruiting --> Recruiting N=99 --> 72
- |||| voxtalisib (SAR245409) / Sanofi, pilaralisib (SAR245408) / Sanofi
Trial completion, Combination therapy: Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer (clinicaltrials.gov) - Apr 8, 2013
P1/2, N=72, Completed, Sponsor: Sanofi
N=99 --> 72 Active, not recruiting --> Completed
- Piqray (alpelisib) / Novartis
Enrollment open: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 4, 2013
P1, N=30, Recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- letrozole / Generic mfg., estradiol valerate / Generic mfg.
Enrollment change: The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles (clinicaltrials.gov) - Mar 30, 2013
P=N/A, N=670, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting --> Recruiting N=900 --> 670
- letrozole / Generic mfg., zoledronic acid / Generic mfg.
Trial completion: Letrozole With or Without Zoledronate in Treating Healthy Postmenopausal Women With High Breast Density (clinicaltrials.gov) - Mar 20, 2013
P=N/A, N=0, Completed, Sponsor: University of Virginia
N=900 --> 670 Active, not recruiting --> Completed
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical: Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients (clinicaltrials.gov) - Mar 17, 2013
P=N/A, N=52, Completed, Sponsor: University of Michigan Cancer Center
- ||| BMS-754807 / BMS
Enrollment change: Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors (clinicaltrials.gov) - Mar 13, 2013
P2, N=100, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed N=59 --> 100